NCT02384954View on ClinicalTrials.gov

QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

April 17, 2015

Primary Completion Date

December 13, 2020

Study Completion Date

December 13, 2020

Conditions
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma
Interventions
BIOLOGICAL

Rituximab

Intravenous infusion 375 mg/m\^2.

BIOLOGICAL

N-803

Intravenous infusion for Phase 1 cohort 1, 2 and 3; subcutaneous injection for Phase 1 cohort 4, 5, 6 and 7. Phase 2 dosing was based off of the MTD determined in Phase 1.

Trial Locations (4)

29425

Medical University of South Carolina, Charleston

43210

The Ohio State University, Columbus

55455

University of Minnesota Cancer Center, Minneapolis

63110

Washington University School of Medicine Oncology, St Louis

Sponsors

Lead Sponsor

Altor BioScience
All Listed Sponsors
lead

Altor BioScience

INDUSTRY